Show simple item record

dc.contributor.authorMurphy, Alexander D
dc.contributor.authorMorgan, Robert D
dc.contributor.authorClamp, Andrew R
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2021-11-26T10:04:37Z
dc.date.available2021-11-26T10:04:37Z
dc.date.issued2021en
dc.identifier.citationMurphy AD, Morgan RD, Clamp AR, Jayson GC. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer [Internet]. British Journal of Cancer. Springer Science and Business Media LLC; 2021.en
dc.identifier.pmid34716396en
dc.identifier.doi10.1038/s41416-021-01605-5en
dc.identifier.urihttp://hdl.handle.net/10541/624760
dc.description.abstractAdvanced epithelial ovarian, fallopian tube and primary peritoneal cancers (EOC) are a leading cause of gynaecological cancer-associated mortality and angiogenesis plays a key role in their growth. Vascular endothelial growth factor inhibitors (VEGFi) disrupt angiogenesis and improve the response rate, progression-free survival and in some cases, overall survival, when administered with and following cytotoxic chemotherapy, irrespective of the platinum sensitivity of EOC. Recent data have identified new indications for VEGFi in EOC: repeated exposure to VEGFi in the first- and then second-line treatment has sustained clinical efficacy; combinations of VEGFi with poly (ADP-ribose) polymerase inhibitors (PARPi) have proven effective as first-line or second-line maintenance regimens. However, recent trial data have not shown improved outcomes with combinations of VEGFi and immune checkpoint inhibitors. There remains a critical need to optimise patient selection for these effective yet somewhat toxic and expensive treatments. The search continues for validated biomarkers to optimise the use of VEGFi, of which the most promising at present is plasma Tie2. Based upon these studies, we propose a model of care incorporating VEGFi into the treatment of EOC, highlighting the need to change from the prescription of single courses of VEGFi, to allow use and re-use as clinically indicated.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-021-01605-5en
dc.titleThe role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian canceren
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, M20 4BX, UKen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record